BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37229950)

  • 21. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
    Skrypek N; Duchêne B; Hebbar M; Leteurtre E; van Seuningen I; Jonckheere N
    Oncogene; 2013 Mar; 32(13):1714-23. PubMed ID: 22580602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging.
    Chen X; Yang Y; Berger I; Khalid U; Patel A; Cai J; Farwell MD; Langer C; Aggarwal C; Albelda SM; Katz SI
    Oncotarget; 2017 Apr; 8(15):24213-24223. PubMed ID: 27655645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting Drug Interactions with Human Equilibrative Nucleoside Transporters 1 and 2 Using Functional Knockout Cell Lines and Bayesian Modeling.
    Miller SR; Zhang X; Hau RK; Jilek JL; Jennings EQ; Galligan JJ; Foil DH; Zorn KM; Ekins S; Wright SH; Cherrington NJ
    Mol Pharmacol; 2021 Feb; 99(2):147-162. PubMed ID: 33262250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.
    Lee HJ; Oh SJ; Lee EJ; Chung JH; Kim Y; Ryu JS; Kim SY; Lee SJ; Moon DH; Kim TW
    Cancer Chemother Pharmacol; 2015 May; 75(5):1005-13. PubMed ID: 25776904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
    Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
    Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 17-Allylamino-17-demethoxygeldanamycin-induced Changes in [
    Lee HJ; Kim DH; Lee SJ
    Anticancer Res; 2017 Jun; 37(6):2993-2999. PubMed ID: 28551637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Demonstration of Nucleoside Transporter Activity in the Nose-to-Brain Distribution of [
    Ponto LLB; Huang J; Walsh SA; Acevedo MR; Mundt C; Sunderland J; Donovan M
    AAPS J; 2017 Dec; 20(1):16. PubMed ID: 29218445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response Monitoring with [
    Heskamp S; Heijmen L; Gerrits D; Molkenboer-Kuenen JDM; Ter Voert EGW; Heinzmann K; Honess DJ; Smith DM; Griffiths JR; Doblas S; Sinkus R; Laverman P; Oyen WJG; Heerschap A; Boerman OC
    Mol Imaging Biol; 2017 Aug; 19(4):540-549. PubMed ID: 27798786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.
    Hagmann W; Jesnowski R; Löhr JM
    Neoplasia; 2010 Sep; 12(9):740-7. PubMed ID: 20824050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts.
    Nakahira S; Nakamori S; Tsujie M; Takeda S; Sugimoto K; Takahashi Y; Okami J; Marubashi S; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Anticancer Res; 2008; 28(1A):179-86. PubMed ID: 18383843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer.
    Eto K; Kawakami H; Kuwatani M; Kudo T; Abe Y; Kawahata S; Takasawa A; Fukuoka M; Matsuno Y; Asaka M; Sakamoto N
    Br J Cancer; 2013 Apr; 108(7):1488-94. PubMed ID: 23492684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
    Nielsen CH; Jensen MM; Kristensen LK; Dahlman A; Fröhlich C; Jacobsen HJ; Poulsen TT; Lantto J; Horak ID; Kragh M; Kjaer A
    Oncotarget; 2015 Nov; 6(35):37486-99. PubMed ID: 26460961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
    Komori S; Osada S; Mori R; Matsui S; Sanada Y; Tomita H; Tokuyama Y; Takahashi T; Yamaguchi K; Yoshida K
    Pancreas; 2010 Nov; 39(8):1284-92. PubMed ID: 20944490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naïve pT2 gallbladder adenocarcinoma patients.
    Espinoza JA; García P; Bizama C; Leal JL; Riquelme I; Weber H; Macanas P; Aguayo G; Viñuela E; Roa JC; Nervi B
    Histopathology; 2016 Apr; 68(5):722-8. PubMed ID: 26266900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pilot study of the diagnostic and prognostic values of FLT-PET/CT for pancreatic cancer: comparison with FDG-PET/CT.
    Nakajo M; Kajiya Y; Tani A; Jinguji M; Nakajo M; Nihara T; Fukukura Y; Yoshiura T
    Abdom Radiol (NY); 2017 Apr; 42(4):1210-1221. PubMed ID: 27891549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.
    Shen Y; Pan Y; Xu L; Chen L; Liu L; Chen H; Chen Z; Meng Z
    Tumour Biol; 2015 Jun; 36(6):4525-34. PubMed ID: 25722110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Limits of [18F]-FLT PET as a biomarker of proliferation in oncology.
    McKinley ET; Ayers GD; Smith RA; Saleh SA; Zhao P; Washington MK; Coffey RJ; Manning HC
    PLoS One; 2013; 8(3):e58938. PubMed ID: 23554961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A study on the antitumor effect of gemcitabine polybutylcy- anoacrylate nanoparticles coupled with Mucin 1 monoclonal antibody on pancreatic cancer
    Zhang L; Zhu J; Hou Y; Li C; Liu H
    J Cancer Res Ther; 2021 Dec; 17(7):1702-1708. PubMed ID: 35381742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of 5-fluoruracil treatment on 3'-fluoro-3'-deoxythymidine (FLT) transport and metabolism in proliferating and non-proliferating cultures of human tumor cells.
    Plotnik DA; McLaughlin LJ; Krohn KA; Schwartz JL
    Nucl Med Biol; 2012 Oct; 39(7):970-6. PubMed ID: 22560972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Equilibrative Nucleoside Transporter 1 (ENT1,
    Cerveny L; Ptackova Z; Ceckova M; Karahoda R; Karbanova S; Jiraskova L; Greenwood SL; Glazier JD; Staud F
    Drug Metab Dispos; 2018 Nov; 46(11):1817-1826. PubMed ID: 30097436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.